Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more

Recent & Breaking News (NDAQ:PHAT)

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHAT

PR Newswire August 4, 2022

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Business Wire August 4, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 4, 2022

PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm

Business Wire August 3, 2022

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors

Business Wire August 3, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Business Wire August 3, 2022

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 3, 2022

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors

Business Wire August 3, 2022

The Law Offices of Frank R. Cruz Announces Investigation of Phathom Pharmaceuticals, Inc. (PHAT) on Behalf of Investors

Business Wire August 2, 2022

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Business Wire August 2, 2022

EQUITY ALERT: Rosen Law Firm Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Class Action Investigation - PHAT

Business Wire August 2, 2022

Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

GlobeNewswire August 2, 2022

Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

GlobeNewswire May 25, 2022

Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

GlobeNewswire May 24, 2022

Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

GlobeNewswire May 17, 2022

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

GlobeNewswire May 10, 2022

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

GlobeNewswire May 4, 2022

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA(TM) TRIPLE PAK(TM) (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA(TM) DUAL PAK(TM) (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

GlobeNewswire May 3, 2022

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

GlobeNewswire April 26, 2022